Off-the-Shelf Cancer Vaccine Works as Well as Personalized Versions in Mouse Breast Cancer
A shared frameshift peptide vaccine reduced tumors and metastases as effectively as personalized cancer vaccines in mice, potentially eliminating the need for custom vaccine manufacturing.
Quick Facts
What This Study Found
Both personal cancer vaccines (PCVs) and the shared FAST vaccine reduced primary tumor incidence, tumor growth, and lung metastases as monotherapies and in combination with anti-PD-L1/CTLA-4 checkpoint inhibitors. The FAST vaccine induced robust T-cell responses.
Key Numbers
200 FSP microarray; top 10 peptides per vaccine; both PCV and FAST reduced tumors and metastases; combined with anti-PD-L1 and anti-CTLA-4
How They Did This
Mouse mammary cancer model (4T1) with frameshift peptide microarray screening. Compared personal vaccines (top 10 per mouse) vs shared FAST vaccines (top 10 across all mice). Evaluated with/without checkpoint inhibitors. Measured tumor clearance, metastases, and immune response via ELISPOT, ELISA, and flow cytometry.
Why This Research Matters
Personalized cancer vaccines are expensive, slow to produce, and not feasible for all patients. If shared antigen vaccines work as well, cancer immunotherapy could become accessible to far more patients.
The Bigger Picture
This work addresses a major bottleneck in cancer immunotherapy — the cost and complexity of personalized vaccines. By identifying shared antigens from predictable RNA errors rather than DNA mutations, it opens a path to mass-produced cancer vaccines.
What This Study Doesn't Tell Us
Mouse model only — human tumors are more heterogeneous. The 4T1 model may not represent all solid tumor types. Sample sizes not clearly reported. RNA-based frameshift antigens in human cancers need validation.
Questions This Raises
- ?Do human tumors share enough frameshift peptide antigens to make FAST vaccines broadly effective?
- ?How does the FAST approach perform against tumor types with different mutation burdens?
- ?What is the optimal combination strategy with checkpoint inhibitors for FAST vaccines?
Trust & Context
- Key Stat:
- Shared = Personal efficacy Off-the-shelf FAST vaccine matched personalized cancer vaccines in tumor reduction and metastasis control in mice
- Evidence Grade:
- Preliminary — promising mouse model results but no human data yet. The 4T1 model is well-established but represents only one tumor type.
- Study Age:
- Published in 2020; frameshift neoantigen vaccines remain an active area of research with growing clinical interest.
- Original Title:
- Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
- Published In:
- BMC immunology, 21(1), 25 (2020)
- Authors:
- Peterson, Milene, Murphy, Sierra Nicole, Lainson, John, Zhang, Jian, Shen, Luhui, Diehnelt, Chris W, Johnston, Stephen Albert
- Database ID:
- RPEP-05067
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What are frameshift peptides and why do they matter for cancer vaccines?
Frameshift peptides are abnormal protein fragments created when cells make errors reading RNA. Cancer cells produce these more frequently, making them recognizable targets for the immune system — and because they come from predictable errors, they can be identified in advance.
Why would a shared vaccine be better than a personalized one?
Personalized cancer vaccines require sequencing each patient's tumor, predicting antigens, and manufacturing a one-time vaccine — a process taking weeks and costing tens of thousands of dollars. A shared vaccine could be mass-produced and available immediately.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05067APA
Peterson, Milene; Murphy, Sierra Nicole; Lainson, John; Zhang, Jian; Shen, Luhui; Diehnelt, Chris W; Johnston, Stephen Albert. (2020). Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.. BMC immunology, 21(1), 25. https://doi.org/10.1186/s12865-020-00350-3
MLA
Peterson, Milene, et al. "Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.." BMC immunology, 2020. https://doi.org/10.1186/s12865-020-00350-3
RethinkPeptides
RethinkPeptides Research Database. "Comparison of personal and shared frameshift neoantigen vacc..." RPEP-05067. Retrieved from https://rethinkpeptides.com/research/peterson-2020-comparison-of-personal-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.